Abstract: A method for treating pulmonary hypertension and other diseases involving a defect in collagen metabolism, by administration of an effective amount of a liposome encapsulated copolymer conjugate antifibrotic composition, is disclosed. The antifibrotic agent is preferably a proline analog, such as cis-4-hydroxy-L-proline (cHyp). Consistent, high loadings (>98%) of the antifibrotic agent are achieved by first forming a dipeptide with L-lysine, after which the dipeptide is copolymerized with the polymer component to form the copolymer conjugate. The polymer is preferably poly(ethylene glycol) having a weight average molecular weight of from about 500 to about 15,000. There is thus provided the efficient delivery and rateable release of the antifibrotic agent to inhibit collagen accumulation and thereby treat the diseases involved.

Abstract: A method of sterilizing objects as well as the sterilized objects obtained from the method are disclosed. The method involves contacting an object such as a medical device to be reused with polycationic dendrimer under conditions which result in rendering a conformationally altered protein (e.g. a prion) non-infectious. A disinfecting agent or surgical scrub composition which comprises the dendrimers is also disclosed as are gelatin capsules treated with polycationic dendrimers.

Abstract: The present invention relates to graft polymer which is characterized in that it is formed by graft polymerization of structural units containing. a quaternary ammonium group represented by general formula (A), (R2 and R3 each represent an alkyl group with from 1 to 3 carbons, and R4 represents an alkyl group with from 3 to 18 carbons. X represents at least one type of ion selected from halogen, sulphate, hydroxide and carboxylic acid ions.), preferably to graft polymer where the structural units containing a quaternary ammonium group represented by general formula (A) are structural units which are represented by general formula (I), (R1 represents at least one species selected from hydrogen, the methyl group and the ethyl group, and n represents an integer in the range 1 to 12. A represents at least one species selected from O, S and NR5. R5 represents hydrogen or an alkyl group with 1 to 12 carbons.

Abstract: Water-soluble and/or water-dispersible comb polymers consisting of a polymer main chain and polyester side-arms which contain sulphone groups and are linked to said polymer main chain via ester groups.

Abstract: A hydrophilic separating carrier particle comprising a copolymerized hydrophilic monomer and hydrophilic crosslinkable monomer, and a process of producing thereof is disclosed.

Abstract: This invention pertains to disulfide-linked conjugates of therapeutic agents containing at least one thioamide group with polymer comprising at least one thiol group, so as to provide a controlled release pharmaceutical composition for administration to animals for the prophylaxis or treatment of various conditions or diseases. The therapeutic agent conjugate may comprise an inactive or weakly active prodrug form which may be converted into the original therapeutic compound by the natural action of reducing agents in vivo. The composition may comprise a mixture of polymers each with a different thioamide-containing agent attached, or a polymer conjugated with a mixture of thioamide-containing agents.

Abstract: The present invention relates to an antibiotic(s)-polymer combination, which under physiological conditions guarantees the continuous release of antibiotics over a period of several days and can be used in human and veterinary medicine. The invented antibiotic(s)-polymer combination is whereinin a homogeneous polymer mixture, consisting of one or more hydrophobic polymers from the groups of poly(methacrylic acid esters), the poly(acrylic acid esters) and the poly(methacrylic acid ester-co-acrylic acid esters) and one or more hydrophilic polymers from the group of polyethers, one or more slightly water-soluble antibiotics from the groups of aminoglycoside antibiotics, the lincosamide antibiotics, the tetracycline antibiotics and quinolone antibiotics, possibly an easily water-soluble antibiotic from the groups of aminoglycoside antibiotics, the lincosamide antibiotics and the tetracycline antibiotics, and possibly one or more organic adjuvants are suspended, and that this suspension forms a composite.

Abstract: To inhibit, prophylactically or therapeutically, a bacterial, yeast, fungal, or parasitic agent in a patient, an effective amount of a dendrimer is administered to the patient, which dendrimer has a plurality of terminal groups, at least one of which has an anionic- or cationic-moiety covalently bonded or linked thereto. The anionic-containing moiety is not a disaccharide or oligosaccharide moiety, and, where the anionic-containing moiety is a neuraminic- or sialic acid-containing. moiety, it is modified in the 4-position by substitution with an amino, amido, cyano, azido or guanido group, or is unsaturated.

Abstract: An antimicrobial coating. The antimicrobial coating contains a water-insoluble polymer having a first ionic group, and an antimicrobial agent having a second ionic group with a charge opposite to that of the first ionic group; wherein the antimicrobial agent is attached to the water-insoluble polymer via an ionic bond between the first ionic group and the second ionic group.

Abstract: This invention pertains to disulfide-linked conjugates of therapeutic agents containing at least one thioamide group with polymer comprising at least one thiol group, so as to provide a controlled release pharmaceutical composition for administration to animals for the prophylaxis or treatment of various conditions or diseases. The therapeutic agent conjugate may comprise an inactive or weakly active prodrug form which may be converted into the original therapeutic compound by the natural action of reducing agents in vivo. The composition may comprise a mixture of polymers each with a different thioamide-containing agent attached, or a polymer conjugated with a mixture of thioamide-containing agents.

Abstract: A polymeric composition capable of releasing nitric oxide under physiological conditions which includes a biopolymer, such as a peptide, polypeptide, protein, oligonucleotide or nucleic acid, to which is bound a nitric oxide-releasing N2O2− functional group; pharmaceutical compositions comprising the polymeric composition; and methods of treating biological disorders in which dosage with nitric oxide is therapeutic.

Abstract: Polystyrene sulfonate (PSS) is a known immune-modulation drug for complement inhibition. Our due diligent review of this drug identifies it as a broad-spectrum immune modulation drug that therapeutically impacts innate and adaptive immune functions. The drug is first of a class of drug that modulates immune responses in accordance to recent advances of immunology. The therapeutic applications with relation to HIV are detailed.

Abstract: A method for inactivating pathogens is provided. This method generally comprises the application of an effective amount of inhibitory compounds, preferably as a topical formulation, either alone or in combination with a pharmaceutically acceptable carrier or diluent. The inhibitory compounds include a copolymer of maleic acid and styrenesulfonic acid, polyvinyl phthalate sulphate, and their salts. The method can be used for preventing transmission and infection of sexual transmitted diseases, for treating and preventing bacterial vaginitis, and as a contraceptive method. These contraceptives generally have fewer side effects than conventional vaginal contraceptives (e.g., Nonoxynol-9). For example, the compounds useful in the methods of the invention not only are not toxic to natural and beneficial flora and, thus, do not upset the local microbiological balance, but also help maintain a low pH in the vaginal environment.

Abstract: A method for removing bile salts from a patient that includes administering to the patient a therapeutically effective amount of a non-absorbable amine polymer characterized by a repeat unit having the formula: and salts thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.

Abstract: Polyazo compounds, which include low molecular weight drugs having a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure, formed into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems having these polyazo compounds as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.

Abstract: A method of sterilizing objects as well as the sterilized objects obtained from the method are disclosed. The method involves contacting an object such as a medical device to be reused with polycationic dendrimer under conditions which result in rendering a conformationally altered protein (e.g. a prion) non-infectious. A disinfecting agent or surgical scrub composition which comprises the dendrimers is also disclosed as are gelatin capsules treated with polycationic dendrimers.

Abstract: The present invention relates to the discovery that certain anionic polymers have useful antibacterial activity.

Abstract: The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.

Abstract: The present invention is directed to monomeric and polymeric compositions based upon polymeric urethane surfactants which are derived from linear, branched, or aromatic compounds of synthetic or natural origin, preferably from tertiary amines and diisocyanate compounds. The urethane polymers of the present invention may be in the form of betaines, quaternium salts, tertiary amine salts or N-oxides. The compounds of the present invention may be incorporated into personal care formulations such as cosmetics, dental care products and toiletries to improve at least one and preferably two or more characteristics of such formulations.

Abstract: A cyanoacrylate adhesive is applied to non-suturable, non-sterile wound surfaces to protect and/or treat such surfaces, to promote wound healing and to retard infection of the wound.

Abstract: An assay comprises contacting cells containing a conformationally altered protein with test compound and determining if the altered protein is cleared. The cells may be scrapie-infected neuroblastoma cells. Another assay comprises contacting organ or tissue homogenate (at pH 5.0 or less) with test compound to determine if altered protein in the homogenate is cleared. The homogenate may be brain homogenate from a transgenic mouse infected with human prions. Compounds which are found to clear the altered protein are useful in preventing, arresting and/or reversing (i.e. treating) a disease associated with the conformationally altered protein.

Abstract: What is claimed are copolymers consisting essentially of from 1 to 90% by weight of the repetitive structural unit of the formula (1) 1

Abstract: A method of sterilizing objects as well as the sterilized objects obtained from the method are disclosed. The method involves contacting an object such as a medical device to be reused with polycationic dendrimer under conditions which result in rendering a conformationally altered protein (e.g. a prion) non-infectious. A disinfecting agent or surgical scrub composition which comprises the dendrimers is also disclosed as are gelatin capsules treated with polycationic dendrimers.

Abstract: A physiologically acceptable composition, in particular a cosmetic composition, comprising at least one liquid fatty phase which comprises (i) at least one structuring polymer having a polymer skeleton which comprises at least one hydrocarbon-based repeating unit comprising at least one hetero atom; and (ii) at least one pasty fatty substance.

Abstract: Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Abstract: The present invention relates to a method of treating a viral infection in an animal, such as a human, by administering to the animal a therapeutically effective amount of a polymer comprising a plurality of pendant hydrophobic groups and a plurality of pendant acid functional groups. The acid functional groups are connected directly to the polymer backbone or via an aliphatic spacer group of 1 to about 20 atoms in length.

Abstract: An antiviral compound comprises a dendrimer such as a polyamidoamine or polyly sine dendrimer having a plurality of terminal groups, wherein at least one of the terminal groups has an anionic- or cationic-containing moiety bonded thereto, particularly a sulfonic acid-containing, carboxylic acid-containing or trimethylammonium-containing moiety or the like.